Connie Johnson Breast Cancer Research Lab


Neoadjuvant interferons: critical for effective PD-1 based immunotherapy in TNBC
Brockwell, N. K.; Owen, K. L.; Zanker, D.; Spurling, A.; Rautela, J.; Duivenvoorden, H. M.; Baschuk, N.; Caramia, F.; Loi, S.; Darcy, P. K.; Lim, E.; Parker, B. S.
Cancer Immunology Research 5(10):871-884, 2017
Window of opportunity treatment in breast cancer
Chen, J.; Easwaralingam, N.; Warrier, S.; Ong, A.; Carson, E. K.; Mak, C.; Snook, K.; Middleton, K.; Parker, A.; Palmieri, C.; Spillane, A.; Mann, G. B.; Lim, E.; Segara, D.
ANZ JOURNAL OF SURGERY 90(1-2):34-40, 2020
Immunoprofiling of breast cancer antigens using antibodies derived from local lymph nodes
Young, A. R.; Duarte, J. D. G.; Coulson, R.; O'Brien, M.; Deb, S.; Lopata, A.; Behren, A.; Mathivanan, S.; Lim, E.; Meeusen, E.
Cancers 11(5):682, 2019
Non-canonical AR activity facilitates endocrine resistance in breast cancer
Chia, K.; Milioli, H.; Portman, N.; Laven-Law, G.; Coulson, R.; Yong, A.; Segara, D.; Parker, A.; Caldon, C. E.; Deng, N.; Swarbrick, A.; Tilley, W. D.; Hickey, T. E.; Lim, E.
ENDOCRINE-RELATED CANCER 26(2):251-264, 2019
Testosterone therapy considerations in oestrogen, progesterone and androgen receptor-positive breast cancer in a transgender man
Light, M.; McFarlane, T.; Ives, A.; Shah, B.; Lim, E.; Grossmann, M.; Zajac, J. D.; Cheung, A. S.
CLINICAL ENDOCRINOLOGY 93(3):355-357, 2020
The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis
Lee, K. W. C.; Lord, S.; Finn, R. S.; Lim, E.; Martin, A.; Loi, S.; Lynch, J.; Friedlander, M.; Lee, C. K.
Secreted tumor antigens - immune biomarkers for diagnosis and therapy
Meeusen, E. N.; Lim, E.; Mathivanan, S.
PROTEOMICS 17(23-24):1600442, 2017
Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic
Kumar, S.; Freelander, A.; Lim, E.
Cancers 13(19):4972, 2021
The management of HER2-positive early breast cancer: Current and future therapies
Chen, J.; Colosimo, M.; Lim, E.
Asia Pacific Journal of Clinical Oncology 17 Suppl 6:3-12, 2021
Vinorelbine potently induces placental cell death, does not harm fertility and is a potential treatment for ectopic pregnancy
Hastie, R.; Lim, E.; Sluka, P.; Campbell, L.; Horne, A. W.; Ellett, L.; Hannan, N. J.; Brownfoot, F.; Kaitu'u-Lino, T. J.; Tong, S.
EBioMedicine 29:166-176, 2018
Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer
de Boer, R.; Hui, R.; Lim, E.; Yeo, B.; Zdenkowski, N.
Asia-Pacific Journal of Clinical Oncology 16 Suppl 5:3-14, 2020
The International Academy of Cytology Yokohama system for reporting breast fine-needle aspiration biopsy cytopathology
Field, A. S.; Raymond, W. A.; Rickard, M.; Arnold, L.; Brachtel, E. F.; Chaiwun, B.; Chen, L.; Di Bonito, L.; Kurtycz, D. F. I.; Lee, A. H. S.; Lim, E.; Ljung, B. M.; Michelow, P.; Osamura, R. Y.; Pinamonti, M.; Sauer, T.; Segara, D.; Tse, G.; Vielh, P.; Chong, P. Y.; Schmitt, F.
ACTA CYTOL 63(4):257-273, 2019
Renewed interest in the progesterone receptor in breast cancer
Lim, E.; Palmieri, C.; Tilley, W. D.;
British Journal of Cancer 115(8):909-911, 2016
The role of MDM2 and MDM4 in breast cancer development and prevention
Haupt, S.; Vijayakumaran, R.; Panimaya, J.; Burgess, A.; Lim, E.; Haupt, Y.
Journal of Molecular Cell Biology 9(1):53-61, 2017
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia
Grossmann, M.; Ramchand, S. K.; Milat, F.; Vincent, A.; Lim, E.; Kotowicz, M. A.; Hicks, J.; Teede, H.
CLINICAL ENDOCRINOLOGY 89(3):280-296, 2018
Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
Boyle, F.; Beith, J.; Burslem, K.; de Boer, R.; Hui, R.; Lim, E.; McCarthy, N.; Redfern, A.; Woodward, N.
Asia-Pacific Journal of Clinical Oncology 14 Suppl 4:3-11, 2018
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer
Hickey, T. E.; Selth, L. A.; Chia, K. M.; Laven-Law, G.; Milioli, H. H.; Roden, D.; Jindal, S.; Hui, M.; Finlay-Schultz, J.; Ebrahimie, E.; Birrell, S. N.; Stelloo, S.; Iggo, R.; Alexandrou, S.; Caldon, C. E.; Abdel-Fatah, T. M.; Ellis, I. O.; Zwart, W.; Palmieri, C.; Sartorius, C. A.; Swarbrick, A.; Lim, E.; Carroll, J. S.; Tilley, W. D.
NATURE MEDICINE 27(2):310-320, 2021
CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care
Hui, R.; de Boer, R.; Lim, E.; Yeo, B.; Lynch, J.
Asia Pacific Journal of Clinical Oncology 17 Suppl 1:3-14, 2021
Attitudes of patients with metastatic cancer towards research biopsies
Robinson, D. H.; Churilov, L.; Lin, N. U.; Lim, E.; Seah, D.
Asia-Pacific Journal of Clinical Oncology 14(3):231-238, 2018
Estrogen receptor signaling is reprogrammed during breast tumorigenesis
Chi, D.; Singhal, H.; Li, L.; Xiao, T.; Liu, W.; Pun, M.; Jeselsohn, R.; He, H.; Lim, E.; Vadhi, R.; Rao, P.; Long, H.; Garber, J.; Brown, M.
Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling
Roswall, P.; Bocci, M.; Bartoschek, M.; Li, H.; Kristiansen, G.; Jansson, S.; Lehn, S.; Sjolund, J.; Reid, S.; Larsson, C.; Eriksson, P.; Anderberg, C.; Cortez, E.; Saal, L. H.; Orsmark-Pietras, C.; Cordero, E.; Haller, B. K.; Hakkinen, J.; Burvenich, I. J. G.; Lim, E.; Orimo, A.; Hoglund, M.; Ryden, L.; Moch, H.; Scott, A. M.; Eriksson, U.; Pietras, K.
NATURE MEDICINE 24(4):463-473, 2018
Sensitizing HR-proficient cancers to PARP inhibitors
Lim, E.; Johnson, S. F.; Geyer, M.; Serra, V.; Shapiro, G. I.
Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer
Lim, E.; Beith, J.; Boyle, F.; de Boer, R.; Hui, R.; McCarthy, N.; Redfern, A.; Wade, T.; Woodward, N.
Asia-Pacific Journal of Clinical Oncology 14 Suppl 4:12-21, 2018
MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer
Portman, N.; Chen, J.; Lim, E.
Frontiers in Oncology 11:777867, 2021
Pushing estrogen receptor around in breast cancer
Lim, E.; Tarulli, G.; Portman, N.; Hickey, T.; Tilley, W. D.; Palmieri, C.;
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary
Grossmann, M.; Ramchand, S. K.; Milat, F.; Vincent, A.; Lim, E.; Kotowicz, M. A.; Hicks, J.; Teede, H. J.
Estrogen receptor positive breast cancer patient derived xenograft models in translational research.
Chia, K.; Freelander, A.; Kumar, S.; Parker, A.; Segara, D.; Portman, N.; Lim, E.
Current Opinion in Endocrine and Metabolic Research 15:31-36, 2020
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Portman, N.; Milioli, H. H.; Alexandrou, S.; Coulson, R.; Yong, A.; Fernandez, K. J.; Chia, K. M.; Halilovic, E.; Segara, D.; Parker, A.; Haupt, S.; Haupt, Y.; Tilley, W. D.; Swarbrick, A.; Caldon, C. E.; Lim, E.